Table 1.
Baseline characteristics of patients (n = 100) and comparison with the MITO16A/MaNGO-OV2 population (n = 398)
| Features | HRR sample, n (%) | MITO16A population, n (%) |
|---|---|---|
| Age (years), median (IQR) | 57.8 (50.0-66.3) | 59.2 (49.9-66.5) |
| Age category: | ||
| • <65 years | 70 (70.0) | 278 (70.0) |
| • ≥65 years | 30 (30.0) | 120 (30.0) |
| ECOG performance status: | ||
| • 0 | 80 (80.0) | 315 (79.0) |
| • 1-2 | 20 (20.0) | 83 (21.0) |
| Residual disease: | ||
| • None | 36 (36.0) | 153 (38.0) |
| • ≤1 cm | 25 (25.0) | 72 (18.0) |
| • >1 cm/not operated | 39 (39.0) | 173 (43.0) |
| FIGO stage: | ||
| • IIIB | 9 (9.0) | 36 (9.0) |
| • IIIC | 72 (72.0) | 275 (69.0) |
| • IV | 19 (19.0) | 87 (22.0) |
| Histology: | ||
| • Serous grade 3 | 98 (98.0) | 333 (84.0) |
| • Low-grade serous | 0 (0) | 13 (3.0) |
| • Endometrioid grade 3 | 2 (2.0) | 9 (2.0) |
| • Clear cell | 0 (0) | 11 (3.0) |
| • Mucinous | 0 (0) | 3 (1.0) |
| • Mixed | 0 (0) | 4 (1.0) |
| • Other | 0 (0) | 25 (6.0) |
ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynaecology and Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique); HRR, homologous recombination repair; IQR, interquartile range.